PWAM
AVTX icon

Park West Asset Management’s Avalo Therapeutics AVTX Stock Holding History

Park West Asset Management’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-32
Closed -$385K – 64
2016
Q3 		$385K Hold
32
– – 0.04% 60
2016
Q2 		$200K Hold
32
– – 0.02% 67
2016
Q1 		$340K Buy
+32
New +$316K 0.03% 64

Other funds holding AVTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AIM
Acrospire Investment Management Chicago, Illinois $107M AUM 37.25% 1-Year Est. Return

Park West Asset Management's AVTX Position: Q4 2016 in Review

Park West Asset Management sold out of Avalo Therapeutics (AVTX) in Q4 2016, closing a stake of 32 shares — an estimated $385K sold.

Park West Asset Management first reported a position in AVTX in Q1 2016 and held it in 3 quarters. The position peaked at $385K in Q3 2016. 8 funds tracked by Wall St. Rank hold AVTX as of Q4 2016.

  • Park West Asset Management reported no remaining Avalo Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Park West Asset Management sold 32 Avalo Therapeutics shares in Q4 2016, an estimated $385K.
  • Park West Asset Management first reported a position in Avalo Therapeutics in Q1 2016 and held it in 3 quarters.
  • Park West Asset Management's Avalo Therapeutics position peaked at $385K in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q4 2016.

Based on Park West Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.